Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251745 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 908
- Enrollment target
NCT00251745 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 908 participants.
The verdict
NCT00251745, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 908 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily \[QD\]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
Interventions
- DRUG Placebo
- DRUG Dexlansoprazole MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 908 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251745
The ClinicalTrials.gov registry entry for NCT00251745 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 908 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00251745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251745 about?
NCT00251745 is a clinical study titled "Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn". The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily \[QD\]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
What is the current status of trial NCT00251745?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 908 participants. The study started on 2005-12. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00251745?
The interventions under investigation include: Placebo (DRUG), Dexlansoprazole MR (DRUG).
Who is sponsoring clinical trial NCT00251745?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.